Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
Treatment strategies targeting programed cell death 1 (PD-1) or its ligand, PD-L1, have been developed as immunotherapy against tumor progression for various cancer types including non-small cell lung cancer (NSCLC). The recent pivotal clinical trials of immune-checkpoint inhibiters (ICIs) combined...
Main Authors: | Ichidai Tanaka, Masahiro Morise |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/1/245 |
Similar Items
-
Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
by: Ichidai Tanaka, et al.
Published: (2023-08-01) -
PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01) -
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
by: Shuguang Tan, et al.
Published: (2016-11-01) -
Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells
by: Hadia Farrukh, et al.
Published: (2021-05-01) -
Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
by: Hiroo Katsuya, et al.
Published: (2023-11-01)